ClinicalTrials.gg
Not yet recruitingNCT07708181Updated Jul 20, 2026

A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment

A Phase 2 interventional study of SSGJ-613 100 mg Q12W and SSGJ-613 200 mg Q12W in Gout Arthritis, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to determine the efficacy and safety of recombinant anti-interleukin-1β humanized monoclonal antibody injection in Chinese gout participants Initiating Urate-Lowering Treatment

02

Conditions studied

  • Gout Arthritis

Browse trials for

Keywords

  • Gout Arthritis
03

In context

Arthritis, Gouty

47 studies on the registry are indexed under Arthritis, Gouty; 16 are open to participants now.

This study's planned enrollment of 200 is above the median of 140 across 35 interventional studies indexed under Arthritis, Gouty.

Browse Arthritis, Gouty studies →

Lead sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is the lead sponsor of 59 studies on the registry; 22 are open to participants now.

First submitted after Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. became part of 3SBio Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be 18 Years to 75 Years, both male and female.
  • ≤40 kg/m2.
  • Meeting the American College of Rheumatology (ACR) 2015 criteria for the classification of gouty arthritis.
  • ≥4 acute gout flares within 1 year prior to screening

Exclusion criteria

Exclusion Criteria:

  • Gout caused by radiotherapy/chemotherapy, organ transplantation, tumors, etc.
  • Evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis.
  • Presence of severe renal function impairment.
  • Intolerance of subcutaneous injection.
  • Known presence or suspicion of active or recurrent bacterial, fungal, or viral infection at the time of enrollment.
  • within 8 weeks prior to the start of the study.
  • Use of forbidden therapy.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    SSGJ-613 100 mg Q12W

    Drug: SSGJ-613 100 mg Q12W

  • Experimental
    SSGJ-613 200 mg Q12W

    Drug: SSGJ-613 200 mg Q12W

  • Active comparator
    Colchicine 0.5mg

    Drug: Colchicine 0.5 mg

  • Experimental
    SSGJ-613 100 mg Q4W

    Drug: SSGJ-613 100 mg Q4W

Interventions

06

What researchers measure

Primary outcomes

  1. Numbers of acute gout flares

    Time frame: 24 weeks

Secondary outcomes

  1. Numbers of acute gout flares

    Time frame: 12 weeks

  2. Proportions of subjects with at least 1 acute gout flare

    Time frame: 12、24、48weeks

  3. Time from randomization to first acute flare.

    Time frame: 12、24、48 Weeks

  4. Numbers of acute gout flares

    Time frame: 12、24 Weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2026
First posted
Jul 16, 2026
StartEst.
Aug 2, 2026
Primary completionEst.
Aug 11, 2027
CompletionEst.
Apr 19, 2028
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07708181
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Aug 2, 2026 (estimated)
Primary completion
Aug 11, 2027 (estimated)
Completion
Apr 19, 2028 (estimated)
Last update
Jul 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SSGJ-613

Start the discussion